AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector
New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.
Clinical Studies | 27/01/2025 | By Aishwarya
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
The company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.
Clinical Studies | 16/01/2025 | By Aishwarya
Chime Biologics and Waterstone to Advance ADC Development and Manufacturing
Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.
Clinical Studies | 13/11/2024 | By Aishwarya
T-Maximum Pharmaceutical Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy
T-MAXIMUM is currently focusing on advanced-stage solid malignancies, with its lead pipeline product for recurrent high-grade glioma (rHGG) demonstrating breakthrough efficacy and manageable safety in initial clinical studies and obtained Orphan Drug Designation (ODD) from the US FDA.
Clinical Studies | 09/08/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy